Highlights

  • Cann Group Limited (ASX:CAN) reported AUD 3.45 million quarterly revenue.
  • Exports accounted for about 40% of September-quarter revenue.
  • Inventory declined 23% to approximately AUD 4.2 million.
  • The company reported a six-month cash outflow excluding grants of AUD 0.9 million.

Cann Group Limited cultivates and manufactures medicinal cannabis products, with its Mildura Facility supplying pharmaceutical-grade material for domestic and overseas customers. Cann Group (ASX:CAN) traded at AUD 0.006 on 13 November 2026, unchanged for the session. Its latest quarterly update reported higher sales and a greater export contribution following a restructuring of costs and Debt during FY26, while cash conversion and repeat orders remain important operating measures.

Mildura Production and Medicinal Cannabis Markets

Cann Group (ASX:CAN)’s core production asset is its Mildura medicinal cannabis facility in Victoria. It produces Good Manufacturing Practice (GMP) grade material for regulated medical markets, including export customers. Access to those channels depends on product quality, customer specifications, permits and relevant regulatory standards. Cann said its Mildura facility received an A1 good-compliance rating following its most recent Therapeutic Goods Administration inspection.

September-Quarter Sales and Export Activity

For the quarter ended 30 September 2026, Cann reported unaudited Revenue of AUD 3.45 million. The company said this equalled approximately 40% of total FY26 revenue in a single quarter and was about 70% above the average quarterly revenue recorded during the second half of FY26. These comparisons reflect management’s stated quarterly measures and do not establish a full-year revenue trajectory.

Exports represented approximately 40% of September-quarter revenue, versus 16% of FY26 revenue. Cann described additional export orders in hand for the December quarter. The higher overseas contribution is relevant to customer diversification, although order timing and shipment schedules can make individual quarters uneven. European medical cannabis distribution also depends on compliance with Import rules and the requirements of regulated customers.

Cost Reset, Working Capital and Cash Flow

Cann reported that FY26 operating costs before Depreciation declined by 34%. During that financial year, AUD 70.6 million of bank debt was settled for AUD 15.3 million. Its FY26 operating cash outflow was reported at AUD 1.3 million, an 86% reduction, reflecting the company’s balance-sheet and cost-base changes. The debt settlement is a specific historical transaction within FY26 and should not be confused with recurring cash generation.

The September-quarter report described a six-month operating cash outflow excluding grants of AUD 0.9 million, compared with AUD 2.9 million in each of the two preceding six-month periods. The quarter itself showed an approximately AUD 0.7 million outflow and a AUD 0.9 million increase in receivables, which management attributed to timing. Inventory fell by AUD 1.2 million, or 23%, to AUD 4.2 million. Cann also reported deploying internal artificial intelligence tools for planning.

Operational Risks and Upcoming Milestones

The next test is whether reported sales and export orders are converted into collections without a similar increase in working capital needs. Cannabis cultivation and processing carry batch-quality, compliance, Yield and production-cost risks. Foreign customer orders also introduce regulatory, logistics and payment considerations. Inventory reduction can support cash management, but sustaining order fulfilment requires sufficient product availability.

Cann noted Redemption of Obsidian notes and an increase of AUD 2 million in a financing facility during the quarter. Updates on debt commitments, customer receivables and operating expenditure remain relevant when assessing the effect of the FY26 reset. The December-quarter report should provide the next measurable evidence on order conversion and the export sales mix.

Key Insights

Cann Group (ASX:CAN) reported a higher quarterly revenue contribution from exports after changes to its financing and cost structure. The September figures provide evidence of sales activity but do not alone establish sustained profitability or cash generation. Receipts, inventory, export fulfilment and financing terms remain central monitoring points for the medicinal cannabis business.